Therapeutic antibody targeting of individual Notch receptors
- PMID: 20393564
- DOI: 10.1038/nature08878
Therapeutic antibody targeting of individual Notch receptors
Abstract
The four receptors of the Notch family are widely expressed transmembrane proteins that function as key conduits through which mammalian cells communicate to regulate cell fate and growth. Ligand binding triggers a conformational change in the receptor negative regulatory region (NRR) that enables ADAM protease cleavage at a juxtamembrane site that otherwise lies buried within the quiescent NRR. Subsequent intramembrane proteolysis catalysed by the gamma-secretase complex liberates the intracellular domain (ICD) to initiate the downstream Notch transcriptional program. Aberrant signalling through each receptor has been linked to numerous diseases, particularly cancer, making the Notch pathway a compelling target for new drugs. Although gamma-secretase inhibitors (GSIs) have progressed into the clinic, GSIs fail to distinguish individual Notch receptors, inhibit other signalling pathways and cause intestinal toxicity, attributed to dual inhibition of Notch1 and 2 (ref. 11). To elucidate the discrete functions of Notch1 and Notch2 and develop clinically relevant inhibitors that reduce intestinal toxicity, we used phage display technology to generate highly specialized antibodies that specifically antagonize each receptor paralogue and yet cross-react with the human and mouse sequences, enabling the discrimination of Notch1 versus Notch2 function in human patients and rodent models. Our co-crystal structure shows that the inhibitory mechanism relies on stabilizing NRR quiescence. Selective blocking of Notch1 inhibits tumour growth in pre-clinical models through two mechanisms: inhibition of cancer cell growth and deregulation of angiogenesis. Whereas inhibition of Notch1 plus Notch2 causes severe intestinal toxicity, inhibition of either receptor alone reduces or avoids this effect, demonstrating a clear advantage over pan-Notch inhibitors. Our studies emphasize the value of paralogue-specific antagonists in dissecting the contributions of distinct Notch receptors to differentiation and disease and reveal the therapeutic promise in targeting Notch1 and Notch2 independently.
Comment in
-
Anticancer drugs: a Notch closer.Nat Rev Drug Discov. 2010 Jun;9(6):431. doi: 10.1038/nrd3188. Nat Rev Drug Discov. 2010. PMID: 20514065 No abstract available.
Similar articles
-
Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells.Methods. 2012 Sep;58(1):69-78. doi: 10.1016/j.ymeth.2012.07.008. Epub 2012 Jul 27. Methods. 2012. PMID: 22842086 Free PMC article.
-
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.PLoS One. 2010 Feb 8;5(2):e9094. doi: 10.1371/journal.pone.0009094. PLoS One. 2010. PMID: 20161710 Free PMC article.
-
Notch1 and Notch2 receptors regulate mouse and human gastric antral epithelial cell homoeostasis.Gut. 2017 Jun;66(6):1001-1011. doi: 10.1136/gutjnl-2015-310811. Epub 2016 Mar 1. Gut. 2017. PMID: 26933171 Free PMC article.
-
Recent advances on NOTCH signaling in T-ALL.Curr Top Microbiol Immunol. 2012;360:163-82. doi: 10.1007/82_2012_232. Curr Top Microbiol Immunol. 2012. PMID: 22673746 Review.
-
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16. Cell Signal. 2014. PMID: 24140475 Review.
Cited by
-
Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells.Methods. 2012 Sep;58(1):69-78. doi: 10.1016/j.ymeth.2012.07.008. Epub 2012 Jul 27. Methods. 2012. PMID: 22842086 Free PMC article.
-
Current views on the role of Notch signaling and the pathogenesis of human leukemia.BMC Cancer. 2011 Nov 30;11:502. doi: 10.1186/1471-2407-11-502. BMC Cancer. 2011. PMID: 22128846 Free PMC article. Review.
-
A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions.SLAS Discov. 2020 Sep;25(8):895-905. doi: 10.1177/2472555220932552. Epub 2020 Jun 22. SLAS Discov. 2020. PMID: 32567455 Free PMC article.
-
Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.Front Cell Dev Biol. 2021 May 28;9:649205. doi: 10.3389/fcell.2021.649205. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34124039 Free PMC article. Review.
-
Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.Semin Cell Dev Biol. 2012 Jun;23(4):465-72. doi: 10.1016/j.semcdb.2012.01.016. Epub 2012 Jan 30. Semin Cell Dev Biol. 2012. PMID: 22309842 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous